Table 1.
Baseline clinical characteristics of the PF group and the DP group
| Variable | PF group (N = 41) n (%) |
DP group (N = 45) n (%) |
P-value |
|---|---|---|---|
| Gender | |||
| Male | 29 (70.7) | 31 (68.9) | 0.853 |
| Female | 12 (29.3) | 14 (31.1) | |
| Age (years) | |||
| Median (range) | 59 (45-69) | 58 (40-73) | |
| <60 | 25 (61.0) | 27 (60.0) | 0.926 |
| ≥60 | 16 (39.0) | 18 (40.0) | |
| KPS | |||
| 90 | 33 (80.5) | 39 (86.7) | 0.370 |
| 80 | 8 (19.5) | 5 (11.1) | |
| 70 | 0 (0) | 1 (2.2) | |
| BMI (kg/m2) | |||
| Median (range) | 21.5 (15.7-30.8) | 21.3 (17.1-27.5) | |
| < 18.5 | 6 (14.6) | 4 (8.9) | 0.508 |
| ≥ 18.5 | 35 (85.4) | 41 (91.1) | |
| CCI | |||
| 0 | 31 (75.6) | 31 (68.9) | 0.716 |
| 1 | 10 (24.4) | 13 (28.9) | |
| 3 | 0 (0) | 1 (2.2) | |
| Smoking index | |||
| 0 | 15 (36.6) | 20 (44.4) | 0.755 |
| >0, ≤400 | 10 (24.4) | 10 (22.2) | |
| >400 | 16 (39.0) | 15 (33.3) | |
| Drinking | |||
| No | 28 (68.3) | 30 (66.7) | 0.872 |
| Yes | 13 (31.7) | 15 (33.3) | |
| Tumour location | |||
| Cervical | 7 (17.1) | 5 (11.1) | 0.729 |
| Upper thoracic | 13 (31.7) | 19 (42.2) | |
| Middle thoracic | 16 (39.0) | 15 (33.3) | |
| Lower thoracic | 3 (7.3) | 2 (4.4) | |
| Multiple primary | 2 (4.9) | 4 (8.9) | |
| Tumour length (mm) | |||
| Median (range) | 55 (10-150) | 47 (20-96) | |
| TNM stage * | |||
| IIA, IIB | 4 (9.8) | 9 (20.0) | 0.236 |
| III | 26 (63.4) | 21 (46.7) | |
| IVA | 11 (26.8) | 15 (33.3) |
Abbreviations: BMI = body mass index; CCI = Charlson comorbidity index; KPS = Karnofsky performance status; PF = cisplatin + 5-Fu; DP = docetaxel + cisplatin;
*TNM stage was assessed according to the 6th edition of the American Joint Commission on Cancer (AJCC) staging system.